ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Astragaloside IV protects against ischemia/reperfusion (I/R)-induced kidney injury based on the Keap1-Nrf2/ARE signaling pathway

Su, Yanyan; Xu, Jiaqi; Chen, Siqi; Feng, Junxia; Li, Jingchun; Lei, Zihan; Qiao, Lingyan; Wang, Yaning*; Zeng, Dewang*南方医科大学; 1
Translational Andrology and Urology2022-8DOI: 10.21037/tau-22-505
7被引13阅读
引用收藏
分享

摘要

Background: This study sought to investigate the protective effects of Astragaloside IV ( AS-IV) on ischemia-reperfusion (I/R) renal injury based on the keap1-Nrf2/ARE signaling pathway. @@@ Methods: A total of 36 male Sprague-Dawley rats (aged: 8 weeks; weighing: 200-220 g) were randomly divided into the following 6 groups (n=6 per group): (I) the control group; (II) the sham operation group; (III) the kidney I/R injury group (the I/R group); (IV) the kidney I/R injury group treated with 2 mg/kg of AS-IV (the low-dose group); (V) the kidney I/R injury group treated with 5 mg/kg of AS-IV (the mid-dose group); and (VI) the kidney I/R injury group treated with 10 mg/kg of AS-IV (the high-dose group). Serum creatinine (CRE), serum urea, malondialdehyde ( MDA), and superoxide dismutase ( SOD) were examined using enzyme-linked immunoassay kits. Cell apoptosis and the pathological damage to the renal tissue were determined by terminal deoxynucleotidyl transferase dUTP nick end labeling, hematoxylin and eosin, and periodic acid-Schiff (PAS) staining. The immunohistochemistry, reverse transcription-polymerase chain reaction (RT-PCR), and western blot methods were used to determine the expression of Nrf2, HO-1, Bcl-2 and Bax in the kidney tissue. @@@ Results: In the I/R rat model, the serum CRE level was increased. In the acute kidney injury (AKI) and chronic kidney disease (CKD) models, AS-IV treatment significantly decreased serum CRE levels in a dosedependent manner. AS-IV treatment also reduced the injury of renal tubular epithelial cells, increased the expression levels of Nrf2 and HO-1, decreased the rate of apoptosis, downregulated the level of MDA, and elevated the activity of SOD. In the CKD rat model, the AS-IV treatment groups had reduced renal tubular epithelial cell injury, increased expression levels of Nrf2 and HO-1, decreased MDA levels, and increased SOD activity compared to the I/R group. @@@ Conclusions: AS-IV induced the expression of Nrf2, enhanced the activity of antioxidant enzymes, reduced apoptosis, protected against renal I/R injury, and prevented AKI from transforming into CKD. These findings suggest that AS-IV is a promising drug for treating kidney injury.

学科与关键词

关键词
Astragaloside IVacute kidney injury (AKI)chronic kidney injurykeap1-Nrf2/AREoxidative stress
相关
加载中…
  • Astragaloside IV attenuates indoxyl sulfate-induced injury of renal tubular epithelial cells by inhibiting the aryl hydrocarbon receptor pathway
    Mo, Yenan; Hu, Dongmei; Yu, Wanlin; Ji, Chunlan; Li, Yin; Liu, Xusheng*; Lu, Zhaoyu*Journal of Ethnopharmacology, 2023, 308: 116244.被引 3
  • The BCL2/BAX/ROS pathway is involved in the inhibitory effect of astragaloside IV on pyroptosis in human umbilical vein endothelial cells
    Su, Yi; Yin, Xin; Huang, Xin; Guo, Qianqian; Ma, Mingyuan; Guo, Liheng*PHARMACEUTICAL BIOLOGY, 2022, 60(1): 1812-1818.被引 6
  • Shenkang Injection and Its Three Anthraquinones Ameliorates Renal Fibrosis by Simultaneous Targeting IκB/NF-κB and Keap1/Nrf2 Signaling Pathways
    Luo, Liang-Pu; Suo, Ping; Ren, Li-Li; Liu, Hong-Jiao; Zhang, Yamei; Zhao, Ying-Yong*Frontiers in Pharmacology, 2021, 12: 800522.被引 40
查看全部 →

发表信息

论文状态
公开发表
期刊
Translational Andrology and Urology
发表日期
2022-08
卷期
第 11 卷, 第 8 期
页码
1177-1188
DOI
10.21037/tau-22-505
期刊等级
4区
成果收录
SCIE
资助标注
Guangzhou Medical Key Discipline Construction Project [20212023]; Guangzhou Health Science and Technology Project [20202A010022]; Guangzhou Huadu District Science and Technology Project [20HDWS-024]; Binzhou Medical University "Clinical X" Science and Technology Innovation Projects [BYLCX24]; Binzhou Medical University Xu Rongxiang Foundation [BY2020XRX05]; Health Science and Technology Project of Guangzhou [20211A011113]; Guangzhou Science and Technology project [202102080616, 202201011649]

作者

  • S

    Su, Yanyan (第一作者)

    southern med univ

  • X

    Xu, Jiaqi

    southern med univ

查看全部 9 位作者收起作者
  • C

    Chen, Siqi

    southern med univ

  • F

    Feng, Junxia

    southern med univ

  • L

    Li, Jingchun

    southern med univ

  • L

    Lei, Zihan

    southern med univ

  • Q

    Qiao, Lingyan

    1 · binzhou med univ

  • W

    Wang, Yaning (通讯)

    binzhou med univ

  • Z

    Zeng, Dewang (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417